Biofrontera Inc.

On December 12, 2025, Discovery entered into a Supply Agreement (“Supply Agreement”) with Midas Pharma GmbH (“Midas”). Among other things, the Supply Agreement provides that Midas will supply to Discovery or its contract manufacturers 5-Aminolevulinic Acid Hydrochloride, the active pharmaceutical ingredient used in the manufacture of Ameluz, in amounts as specified therein. Under the terms of the Supply Agreement, Discovery will provide Midas with a twenty-four (24) months non-binding rolling forecast, which shall 1) indicate the anticipated quantity of API required by the company and 2) be updated every twelve (12) months during the term of the agreement. The Supply Agreement has an initial term ending on December 31, 2030, and automatically renews for successive two-year periods unless either party provides at least 12 months’ notice of termination prior to expiration of the then-current term. The Supply Agreement is governed by the laws of Germany.

This description of the Supply Agreement doesnot purport to be complete and is qualified in its entirety by reference to the full text of the Supply Agreement, a copy of which is attached as Exhibits 10.33, respectively, to this Form 10-K and incorporated herein by reference.